Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Why Hims & Hers Stock Tumbled on Tuesday
Hims & Hers Health ( HIMS 7.49%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...
Should You Buy Hims & Hers Stock on the Dip?
Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...
Hims & Hers Stock (HIMS) Soars on Plans to Shutter Acne Treatment Unit
Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of Hims & Hers’ ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...
Citi Sticks to Sell Rating on Hims & Hers (HIMS) Stock as FDA Ruling Clouds Outlook
Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...
Woman Says Her Husband of 6 Years Wants to Stay Married but End Their Romantic Relationship: 'I'm So Broken'
A woman says that her husband recently told her he no longer wants a romantic relationship with her, but would still like to ...
Hims & Hers Stock Is Due for a Crash Diet. The GLP-1 Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
Investing13d
BofA reiterates Hims & Hers stock underperform rating
For investors and stakeholders in Hims & Hers, the FDA's decision offers some regulatory certainty in the near term. The company's stock performance will continue to be influenced by its ability ...